Free Trial
ASX:CSL

CSL (CSL) Stock Price, News & Analysis

CSL logo

About CSL Stock (ASX:CSL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
869,289 shs
Average Volume
N/A
Market Capitalization
$77.43 billion
P/E Ratio
28.02
Dividend Yield
1.56%
Price Target
N/A
Consensus Rating
N/A

Company Overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Receive CSL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

CSL Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Carlisle price target lowered to $390 from $420 at Truist
See More Headlines

CSL Stock Analysis - Frequently Asked Questions

CSL Limited (ASX:CSL) posted its quarterly earnings data on Wednesday, August, 14th. The company reported $4.24 EPS for the quarter, beating analysts' consensus estimates of $4.22 by $0.01. CSL had a trailing twelve-month return on equity of 15.37% and a net margin of 18.41%.

Based on aggregate information from My MarketBeat watchlists, some other companies that CSL investors own include Cochlear (COH), Mineral Resources (MIN), ResMed (RMD), Magellan Financial Group (MFG), NIB (NHF), Accent Group (AX1) and Corporate Travel Management (CTD).

Company Calendar

Last Earnings
8/14/2019
Ex-Dividend for 4/8 Dividend
3/09/2025
Record date for 4/8 Dividend
4/08/2025
Dividend Payable
4/08/2025
Today
5/02/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Rubber And Plastic Products
Current Symbol
ASX:CSL
CIK
N/A
Fax
N/A
Employees
12,500
Year Founded
N/A

Profitability

Trailing P/E Ratio
28.02
Forward P/E Ratio
N/A
P/E Growth
1.29
Net Income
$2.64 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.80 billion
Price / Cash Flow
207.70
Book Value
A$42.52 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$77.43 billion
Optionable
Not Optionable
Beta
0.32
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (ASX:CSL) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners